The primary aim of this open-label pilot trial is to estimate the treatment effect of 100 mg
of oral minocycline twice daily for 90 days, initiated within 30 days of onset of ON, on
functional and structural optic nerve recovery compared to no treatment. The primary outcome
measure that will be used to measure optic nerve recovery is retinal nerve fibre layer (RNFL)
thickness. Other objectives: Secondary outcomes are temporal RNFL thickness, macular volume,
and visual outcomes.